Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 study investigating the efficacy, safety, and tolerability of Dupilumab administered to adult patients with severe atopic dermatitis who are not adequately controlled with or are intolerant to oral cyclosporine A, or when this treatment is not medically advisable

Next Previous
Trial Profile

A phase 3 study investigating the efficacy, safety, and tolerability of Dupilumab administered to adult patients with severe atopic dermatitis who are not adequately controlled with or are intolerant to oral cyclosporine A, or when this treatment is not medically advisable

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dupilumab (Primary)
  • Indications Atopic dermatitis
  • Focus Registrational; Therapeutic Use
  • Acronyms CAFE; LIBERTY AD CAFE
  • Sponsors Regeneron Pharmaceuticals

    • Most Recent Events

    • 20 Feb 2023 Post-hoc pooled data (N=2444) analysis evaluating efficacy and safety of dupilumab in patients aged greater than or equal to 60 years with moderate-to-severe atopic dermatitis from NCT02277743, NCT02277769, NCT02755649, NCT02260986, published in the American Journal of Clinical Dermatology.
    • 01 Feb 2023 Results of post hoc analysis from 6 studies(n=209 from NCT01859988, NCT02277743, NCT02277769, NCT03054428, NCT02260986, NCT02755649) assessing Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis published in the JAMA Dermatology
    • 01 Feb 2022 Results (n=2444) of post hoc analysis form the trials (SOLO 1, SOLO 2, CAFE, and CHRONOS) assessing the sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis, published in the Journal of Dermatological Treatment.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top